Amgen (AMGN)
NASDAQ:AMGN
Want to see AMGN full AI Analyst Report?
AMGN Stock Chart & Stats
$355.30
-$0.21(-0.08%)
At close: 4:00 PM EST
$355.30
-$0.21(-0.08%)
Day’s Range― - ―
52-Week Range$261.43 - $391.29
Previous CloseN/A
Volume614.18K
Average Volume (3M)2.55M
Market Cap
$174.78B
Enterprise Value$223.98B
Total Cash (Recent Filing)$12.04B
Total Debt (Recent Filing)$57.32B
Price to Earnings (P/E)26.1
Beta0.39
Next Earnings
Aug 04, 2026EPS Estimate
5.62Next Dividend Ex-DateN/A
Dividend Yield3%
Share Statistics
EPS (TTM)14.48
Shares Outstanding539,708,250
10 Day Avg. Volume2,563,398
30 Day Avg. Volume2,552,585
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)20.34
Price to Sales (P/S)4.79
P/FCF Ratio21.74
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue6.01
Enterprise Value/Gross Profit8.42
Enterprise Value/Ebitda12.91
Forecast
1Y Price Target
$362.81Price Target Upside2.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
EPS Forecast (FY)22.3
Revenue Forecast (FY)$37.81B
Bulls Say, Bears Say
Bulls Say
AI Partnership And Data AdvantageAnalyst notes that the partnership with NVIDIA to build AI models on one of the largest human datasets could accelerate drug discovery and provide a competitive data advantage across the research pipeline.
Commercial Momentum Of Core ProductsAnalyst emphasizes that durable volume growth for Repatha and strong uptake of growth-stage products like Uplizna support top-line strength and suggest upside to current revenue expectations.
Subcutaneous Tepezza DeliveryAnalyst highlights that late-stage results for subcutaneous Tepezza delivered via an on-body injector could reduce dependence on infusion centers and help the thyroid eye disease franchise return to growth.
Bears Say
Inventory And Reimbursement PressuresAnalyst flags that some reported strength was driven by inventory builds and that Part D redesign combined with a higher contract mix could weigh on the sustainability of commercial sales.
Loss Of Exclusivity RiskAnalyst warns that significant upcoming loss of exclusivity for several major products represents a material headwind to future revenue if not offset by new launches.
MariTide Clinical Uncertainty And CompetitionAnalyst expresses caution that unclear efficacy, tolerability concerns including nausea and vomiting, and strong competition in the obesity market could limit MariTide's commercial prospects.
Amgen News
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $261.43 and its highest was $391.29 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $174.78B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Aug 04, 2026 which is in 89 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Apr 30, 2026. The company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.767 by $0.383.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 5.62.
How many shares outstanding does Amgen have?
Amgen has 539,708,250 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $5.15 in its last earnings report, beating expectations of $4.767. Following the earnings report the stock price went down -4.745%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in AMGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$362.81 (2.11% Upside)
$362.81 (2.11% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 92%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 653.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.15%
12-Months-Change
Fundamentals
Return on Equity
96.65%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Company Deck
AMGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive tone: Amgen reported modest overall product sales growth (4%) while its six key growth drivers delivered strong momentum (24% aggregate growth and ~70% of sales), the company raised full-year revenue and EPS guidance, generated substantial free cash flow, and highlighted significant pipeline progress (notably Meritide, olpasiran, Imdeltra, TEPEZZA) and AI-driven R&D productivity gains. Material challenges were acknowledged, including steep declines in legacy osteoporosis brands (Prolia/XGEVA), rising cost-of-sales pressure, regulatory and trial uncertainties (Tabneos/paused blinatumomab enrollment), and a potentially material IRS audit adjustment for tax years 2016–2018. Overall, the positive commercial momentum, strengthened guidance, robust cash generation, and advancing late-stage pipeline outweigh the notable headwinds and risks discussed during the call.View all AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$362.81
▲(2.11% Upside)
Technical Analysis
Ownership Overview
0.20% Insiders
24.61% Mutual Funds
4.30% Other Institutional Investors
41.29% Public Companies and Individual Investors